H.C. Wainwright analyst Matthew Caufield initiated coverage of Surrozen (SRZN) with a Buy rating and $32 price target Surrozen is advancing novel therapies based on the selective modulation of the Wingless-related integration site pathway, the analyst tells investors in a research note. The firm says the company is developing tissue-specific antibodies that could leverage the body’s biological repair and regeneration mechanisms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN: